BioSpace News Archive

Drug Development

Efficacy and Safety Results From Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

The RADIANCE Part B study evaluated two doses (1 mg and 0.5 mg) of oral ozanimod compared with IFN in 1,320 patients with RMS in 21 countries treated for two years.

October 28, 2017
·
9 min read
Drug Development

Novartis Pivotal Data Show Children and Adolescents With Relapsing MS Had an 82% Lower Relapse Rate With Fingolimod Vs. Interferon Beta-1a

The data also show fingolimod-treated patients had significantly fewer new brain lesions vs. those on intramuscular interferon beta-1a injections.

October 28, 2017
·
15 min read